Praxis Precision Medicines (PRAX) Enterprise Value (2019 - 2026)

Praxis Precision Medicines' Enterprise Value history runs 8 years deep, the most recent figure standing at -$786.9 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 139.9% year-over-year to -$786.9 million in Q1 2026; TTM through Mar 2026 was -$786.9 million, a 139.9% decrease from a year earlier, with the FY2025 full-year figure at -$599.3 million, down 52.67% from the prior year.
• Enterprise Value slipped to -$786.9 million in Q1 2026 per PRAX's latest filing, from -$599.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$56.0 million in Q2 2022 and bottomed at -$786.9 million in Q1 2026.
• The 5-year median for Enterprise Value is -$207.4 million (2024), against an average of -$249.2 million.
• Across the five-year window, Enterprise Value soared 68.14% in 2022 and plunged 382.86% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$61.6 million in 2022, then sank by 31.95% to -$81.3 million in 2023, then plunged by 382.86% to -$392.6 million in 2024, then plunged by 52.67% to -$599.3 million in 2025, then tumbled by 31.29% to -$786.9 million in 2026.
• Per Business Quant, the three latest PRAX Enterprise Value figures stand at -$786.9 million (Q1 2026), -$599.3 million (Q4 2025), and -$267.2 million (Q3 2025).